AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals

Phase 4

Withdrawn

Conditions: Primary Hypercholesterolaemia

First Posted Date: 2006-11-06

Last Posted Date: 2009-03-26

Lead Sponsor: AstraZeneca

Target Recruit Count: 1294

Registration Number: NCT00396240

Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)

Completed

Conditions: Hypercholesterolemia
Coronary Heart Disease

First Posted Date: 2006-11-06

Last Posted Date: 2006-11-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 3889

Registration Number: NCT00396110

ROMEO (Rosuvastatin in Metabolic syndrOme)

Phase 4

Completed

Conditions: Metabolic Syndrome X

Interventions: Drug: Rosuvastatin
Drug: Atorvastatin

First Posted Date: 2006-11-03

Last Posted Date: 2011-07-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 258

Registration Number: NCT00395486

Locations: 🇰🇷
Research Site, Suwon, Korea, Republic of

Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients

Phase 2

Completed

Conditions: Gastroesophageal Reflux Disease (GERD)

First Posted Date: 2006-11-01

Last Posted Date: 2013-03-18

Lead Sponsor: AstraZeneca

Target Recruit Count: 244

Registration Number: NCT00394472

Locations: 🇷🇴
Research Site, Targu Mures, Romania

A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects

Phase 2

Completed

Conditions: Overweight
Obesity

Interventions: Drug: pramlintide acetate 360 mcg
Drug: metreleptin
Drug: placebo-metreleptin 1 mL
Drug: placebo-pramlintide 600 uL
Drug: Pramlintide acetate 180 mcg

First Posted Date: 2006-10-26

Last Posted Date: 2015-04-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 177

Registration Number: NCT00392925

Locations: 🇺🇸
Research Site, Olympia, Washington, United States

Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone

Phase 4

Completed

Conditions: Heart Failure
Ventricular Dysfunction, Left

Interventions: Drug: Captopril
Drug: Enalapril
Drug: Lisinopril
Drug: Ramipril
Drug: Trandolapril
Drug: Bisoprolol
Drug: Carvedilol
Drug: Metoprolol succinate
Drug: Candesartan
Drug: Valsartan
Drug: Eplerenone
Drug: Spironolactone
Drug: Diuretics
Drug: HF treatment according to Swedish guidelines
Procedure: Blood samples
Procedure: The Kansas City Cardiomyopathy Questionnaire (KCCQ)

First Posted Date: 2006-10-25

Last Posted Date: 2012-06-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 252

Registration Number: NCT00391846

Locations: 🇸🇪
Research Site, Vaxjo, Sweden

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

Phase 3

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Clopidogrel
Drug: Ticagrelor

First Posted Date: 2006-10-25

Last Posted Date: 2012-03-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 18624

Registration Number: NCT00391872

Locations: 🇬🇧
Research Site, Swansea, United Kingdom

Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response

Phase 4

Completed

Conditions: Gastroesophageal Reflux

First Posted Date: 2006-10-25

Last Posted Date: 2008-01-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 2000

Registration Number: NCT00392002

Locations: 🇨🇦
Research Site, Toronto, Ontario, Canada

Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Placebo
Drug: Ciclesonide

First Posted Date: 2006-10-25

Last Posted Date: 2017-02-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 528

Registration Number: NCT00392288

Locations: 🇲🇽
Sanofi-Aventis, Mexico, Mexico
🇵🇱
sanofi-aventis Poland, Warszawa, Poland
🇭🇺
Sanofi-Aventis Hungaria, Budapest, Hungary

and more 3 locations

Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder

Phase 3

Completed

Conditions: Anxiety Disorders

Interventions: Drug: Quetiapine XR
Drug: Placebo

First Posted Date: 2006-10-18

Last Posted Date: 2012-04-04

Lead Sponsor: AstraZeneca

Target Recruit Count: 450

Registration Number: NCT00389064

Locations: 🇺🇦
Research Site, Vinnitsa, Ukraine

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy